Clinical Trial Update: Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of the live-attenuated Listeria immunotherapy JNJ-64041757 in non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JNJ-64041757

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED